Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cipralex escitalopram: Phase III; Under review in the U.S. and approved in Europe

Subset analysis of a 170-patient subgroup in a Phase III trial in a total of 357 patients showed a response

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE